We tested this hypothesis by examining the antiobesity effect of SFN on two established genetic models of obesity, namely, the leptin-deficient Lepob/ob and the leptin receptor mutant Leprdb/db mice, both of which develop early-onset hyperphagic obesity due to deficient leptin signaling. The gene discussed is LEPR; the disease is Obesity.